Update on rufinamide in childhood epilepsy
Giangennaro CoppolaClinic of Child and Adolescent Neuropsychiatry, Medical School, University of Salerno, ItalyAbstract: Rufinamide is an orally active, structurally novel compound (1-[(2,6-difluorophenil1)methyl1]-1 hydro 1,2,3-triazole-4 carboxamide), which is structurally distinct from other anti...
Saved in:
| Main Author: | Coppola G |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2011
|
| Subjects: | |
| Online Access: | https://doaj.org/article/e856e9be879d4a43bc052b883c77d175 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
by: Carl E Stafstrom
Published: (2009) -
Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
by: Jessica Gresham, et al.
Published: (2010) -
Update on treatment of partial onset epilepsy: role of eslicarbazepine
by: Markus Rauchenzauner, et al.
Published: (2010) -
Profile of lacosamide and its role in the long-term treatment of epilepsy: a perspective from the updated NICE guideline
by: Delgado Nunes V, et al.
Published: (2013) -
Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review
by: Balagura G, et al.
Published: (2020)